EP3481818B1 - Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble - Google Patents
Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble Download PDFInfo
- Publication number
- EP3481818B1 EP3481818B1 EP17745553.2A EP17745553A EP3481818B1 EP 3481818 B1 EP3481818 B1 EP 3481818B1 EP 17745553 A EP17745553 A EP 17745553A EP 3481818 B1 EP3481818 B1 EP 3481818B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- appropriate amount
- formula
- suitable temperature
- organic solvent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 97
- 230000008569 process Effects 0.000 title claims description 87
- 238000002360 preparation method Methods 0.000 title description 26
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title description 15
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title description 15
- 239000003119 guanylate cyclase activator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 237
- 239000003960 organic solvent Substances 0.000 claims description 74
- -1 pyrazole ester Chemical class 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 62
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 claims description 49
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 38
- 239000003153 chemical reaction reagent Substances 0.000 claims description 36
- 239000003054 catalyst Substances 0.000 claims description 34
- 239000003586 protic polar solvent Substances 0.000 claims description 31
- 229910052751 metal Inorganic materials 0.000 claims description 29
- 239000002184 metal Substances 0.000 claims description 29
- 150000002009 diols Chemical class 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- YLZYSVYZMDJYOT-UHFFFAOYSA-N 2-methoxypyrimidine Chemical compound COC1=NC=CC=N1 YLZYSVYZMDJYOT-UHFFFAOYSA-N 0.000 claims description 25
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 150000001409 amidines Chemical class 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- 150000001408 amides Chemical class 0.000 claims description 21
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 21
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 20
- 239000007858 starting material Substances 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 18
- 239000011707 mineral Substances 0.000 claims description 18
- 238000009901 transfer hydrogenation reaction Methods 0.000 claims description 18
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 13
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 12
- FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 235000019270 ammonium chloride Nutrition 0.000 claims description 8
- 239000003444 phase transfer catalyst Substances 0.000 claims description 8
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 claims description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 7
- 150000003840 hydrochlorides Chemical class 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 5
- 239000011260 aqueous acid Substances 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 230000002152 alkylating effect Effects 0.000 claims description 4
- 230000002862 amidating effect Effects 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 230000000382 dechlorinating effect Effects 0.000 claims description 2
- 239000000543 intermediate Substances 0.000 description 218
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 123
- 238000006243 chemical reaction Methods 0.000 description 113
- 150000001412 amines Chemical class 0.000 description 86
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 67
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 54
- 239000002002 slurry Substances 0.000 description 54
- 238000004128 high performance liquid chromatography Methods 0.000 description 53
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- 239000011541 reaction mixture Substances 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 41
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 36
- 239000002904 solvent Substances 0.000 description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- 239000012065 filter cake Substances 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 29
- 239000007787 solid Substances 0.000 description 29
- 150000003839 salts Chemical class 0.000 description 27
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 25
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 23
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 20
- 125000000217 alkyl group Chemical group 0.000 description 20
- 229910052739 hydrogen Inorganic materials 0.000 description 19
- 239000001257 hydrogen Substances 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 16
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 15
- 229910019213 POCl3 Inorganic materials 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 14
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 14
- 230000008878 coupling Effects 0.000 description 14
- 238000010168 coupling process Methods 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 14
- 235000010755 mineral Nutrition 0.000 description 14
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 description 14
- 239000000010 aprotic solvent Substances 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 229910052763 palladium Inorganic materials 0.000 description 11
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 10
- 239000011736 potassium bicarbonate Substances 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000000908 ammonium hydroxide Substances 0.000 description 8
- 229940045348 brown mixture Drugs 0.000 description 8
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 8
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 7
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000004809 Teflon Substances 0.000 description 7
- 229920006362 Teflon® Polymers 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 150000007529 inorganic bases Chemical class 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- OOMBRKGIWITBLL-UHFFFAOYSA-N (2-fluorophenyl)methylhydrazine Chemical compound NNCC1=CC=CC=C1F OOMBRKGIWITBLL-UHFFFAOYSA-N 0.000 description 5
- QGLIOTYTGRWVPT-UHFFFAOYSA-N 2-(aminomethyl)-1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound NCC(O)(C(F)(F)F)C(F)(F)F QGLIOTYTGRWVPT-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 5
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 5
- 238000005660 chlorination reaction Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- CYSJNTQNMDWAJV-UHFFFAOYSA-N praliciguat Chemical compound C1=C(F)C(NCC(O)(C(F)(F)F)C(F)(F)F)=NC(C2=NN(CC=3C(=CC=CC=3)F)C(C3=NOC=C3)=C2)=N1 CYSJNTQNMDWAJV-UHFFFAOYSA-N 0.000 description 5
- 238000013341 scale-up Methods 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000005576 amination reaction Methods 0.000 description 4
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 4
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- GOWQBFVDZPZZFA-UHFFFAOYSA-N diethyl 2-fluoropropanedioate Chemical compound CCOC(=O)C(F)C(=O)OCC GOWQBFVDZPZZFA-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- WFIZEGIEIOHZCP-UHFFFAOYSA-M potassium formate Chemical compound [K+].[O-]C=O WFIZEGIEIOHZCP-UHFFFAOYSA-M 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 4
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 4
- 235000019254 sodium formate Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical group [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- UXYRXGFUANQKTA-UHFFFAOYSA-N 1,2-oxazole-3-carboxylic acid Chemical compound OC(=O)C=1C=CON=1 UXYRXGFUANQKTA-UHFFFAOYSA-N 0.000 description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
- LIVYVCAUBHXIMI-UHFFFAOYSA-N 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-1h-pyrimidin-6-one Chemical compound C1=C(F)C(O)=NC(C2=NN(CC=3C(=CC=CC=3)F)C(C3=NOC=C3)=C2)=N1 LIVYVCAUBHXIMI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000000460 chlorine Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- ZRKSVHFXTRFQFL-UHFFFAOYSA-N isocyanomethane Chemical compound C[N+]#[C-] ZRKSVHFXTRFQFL-UHFFFAOYSA-N 0.000 description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- DOJOOVGKNBZITK-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazole-3-carboximidamide;hydrochloride Chemical compound Cl.C=1C=CC=C(F)C=1CN1N=C(C(=N)N)C=C1C=1C=CON=1 DOJOOVGKNBZITK-UHFFFAOYSA-N 0.000 description 2
- NYZSKEULTVZUAW-UHFFFAOYSA-N 2,2-bis(trifluoromethyl)oxirane Chemical compound FC(F)(F)C1(C(F)(F)F)CO1 NYZSKEULTVZUAW-UHFFFAOYSA-N 0.000 description 2
- HZGNUVGOBRNWNS-UHFFFAOYSA-N 2-[[[6-chloro-5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC1=C(CN2C(C=3C=CON=3)=CC(C3=NC(=C(F)C(=N3)NCC(C(F)(F)F)(C(F)(F)F)O)Cl)=N2)C=CC=C1 HZGNUVGOBRNWNS-UHFFFAOYSA-N 0.000 description 2
- XDQRQLMGRLFVJW-UHFFFAOYSA-N 3-[5-(4-chloro-5-fluoro-6-methoxypyrimidin-2-yl)-2-[(2-fluorophenyl)methyl]pyrazol-3-yl]-1,2-oxazole Chemical compound ClC1=C(F)C(OC)=NC(C2=NN(CC=3C(=CC=CC=3)F)C(C3=NOC=C3)=C2)=N1 XDQRQLMGRLFVJW-UHFFFAOYSA-N 0.000 description 2
- SGJXCKCBCGRUQQ-UHFFFAOYSA-N 3-[5-(5-fluoro-4-methoxypyrimidin-2-yl)-2-[(2-fluorophenyl)methyl]pyrazol-3-yl]-1,2-oxazole Chemical compound C1=C(F)C(OC)=NC(C2=NN(CC=3C(=CC=CC=3)F)C(C3=NOC=C3)=C2)=N1 SGJXCKCBCGRUQQ-UHFFFAOYSA-N 0.000 description 2
- ZPANOJAXKGHYBC-UHFFFAOYSA-N 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-4-hydroxy-1h-pyrimidin-6-one Chemical compound N1C(=O)C(F)=C(O)N=C1C1=NN(CC=2C(=CC=CC=2)F)C(C2=NOC=C2)=C1 ZPANOJAXKGHYBC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 2
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 2
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 2
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- LSGIIWMOYDZCCN-VQHVLOKHSA-N O1N=C(C=C1)C(/C=C(\C(=O)OCC)/N(C)OC)=O Chemical compound O1N=C(C=C1)C(/C=C(\C(=O)OCC)/N(C)OC)=O LSGIIWMOYDZCCN-VQHVLOKHSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- XNXAZXZVTDKDIL-UHFFFAOYSA-N ethyl 1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazole-3-carboxylate Chemical compound C=1C=CC=C(F)C=1CN1N=C(C(=O)OCC)C=C1C=1C=CON=1 XNXAZXZVTDKDIL-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- DHEWMIAJHISOGS-UHFFFAOYSA-N n-methoxy-n-methyl-1,2-oxazole-3-carboxamide Chemical compound CON(C)C(=O)C=1C=CON=1 DHEWMIAJHISOGS-UHFFFAOYSA-N 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BWIHJLOBZMKPKS-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)pyrimidine Chemical class N1C=CC(C=2N=CC=CN=2)=N1 BWIHJLOBZMKPKS-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 description 1
- JYAHXBWSCRHPMZ-UHFFFAOYSA-N 3-[5-(4,6-dichloro-5-fluoropyrimidin-2-yl)-2-[(2-fluorophenyl)methyl]pyrazol-3-yl]-1,2-oxazole Chemical compound FC1=CC=CC=C1CN1C(C2=NOC=C2)=CC(C=2N=C(Cl)C(F)=C(Cl)N=2)=N1 JYAHXBWSCRHPMZ-UHFFFAOYSA-N 0.000 description 1
- XSFVAQRSZSENGO-UHFFFAOYSA-N 3-benzyl-2h-indazole Chemical compound N1N=C2C=CC=CC2=C1CC1=CC=CC=C1 XSFVAQRSZSENGO-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BNQFOSYFEVDOMJ-UHFFFAOYSA-N 4-chloro-5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-1H-pyrimidin-6-one Chemical compound ClC1=C(C(=NC(=N1)C1=NN(C(=C1)C1=NOC=C1)CC1=C(C=CC=C1)F)O)F BNQFOSYFEVDOMJ-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000288714 Talpidae Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 235000019647 acidic taste Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000001983 dialkylethers Chemical class 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000002124 flame ionisation detection Methods 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910001959 inorganic nitrate Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- IPILPUZVTYHGIL-UHFFFAOYSA-M tributyl(methyl)azanium;chloride Chemical compound [Cl-].CCCC[N+](C)(CCCC)CCCC IPILPUZVTYHGIL-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields.
- the present invention has the additional advantage of involving facile reaction conditions that are amenable to scale up for large scale manufacturing.
- the disclosure also provides novel intermediates useful in the preparation of said compounds.
- Compounds of Formula I and their pharmaceutically acceptable salts are sGC stimulators useful for treating diseases or disorders that benefit from sGC stimulation or from an increase in the concentration of nitric oxide (NO) and/or cyclic guanosine monophosphate (cGMP).
- Compounds of Formula I are also useful intermediates in the preparation of other sGC stimulators, including other compounds of Formula I.
- sGC is the primary receptor for NO in vivo.
- sGC can be activated via both NO-dependent and NO-independent mechanisms.
- sGC converts guanosine-5'-triphosphate (GTP) into the secondary messenger cGMP.
- GTP guanosine-5'-triphosphate
- the increased level of cGMP in turn, modulates the activity of downstream effectors including protein kinases, phosphodiesterases (PDEs) and ion channels.
- NO is synthesized from arginine and oxygen by various nitric oxide synthase (NOS) enzymes and by sequential reduction of inorganic nitrate.
- NOS nitric oxide synthase
- Three distinct isoforms of NOS have been identified: inducible NOS (iNOS or NOS II) found in activated macrophage cells; constitutive neuronal NOS (nNOS or NOS I), involved in neurotransmission and long-term potentiation; and constitutive endothelial NOS (eNOS or NOS III) which regulates smooth muscle relaxation and blood pressure.
- iNOS or NOS II inducible NOS
- nNOS or NOS I constitutive neuronal NOS
- eNOS or NOS III constitutive endothelial NOS
- NO-independent, heme-dependent sGC stimulators displayed several important differentiating characteristics when compared with NO-independent, heme-independent sGC activators. These include crucial dependency on the presence of the reduced prosthetic heme moiety for their activity, strong synergistic enzyme activation when combined with NO and stimulation of the synthesis of cGMP by direct stimulation of sGC, independent of NO.
- the benzylindazole compound YC-1 was the first sGC stimulator to be identified. Additional sGC stimulators with improved potency and specificity for sGC have since been developed.
- WO 2015/089182 , WO 2014/144100 , WO 2013/101830 and WO2016044447 disclose compounds which are useful as stimulators of sGC.
- WO 2017/095697 discloses solid dispersions of amorphous 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidi n-4-yl)amino)methyl)propan-2-ol, which is an sGC stimulator.
- Some compounds of Formula I and their pharmaceutically acceptable salts are sGC stimulators that are useful for treating diseases or disorders that benefit from sGC stimulation or from an increase in the concentration of NO and/or cGMP.
- Other compounds of Formula I are useful as intermediates in the synthesis of other sGC stimulators, including other compounds of Formula I.
- stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in some embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
- a stable compound is one that is not substantially altered when kept at a temperature of 25°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
- a chemically feasible compound is a compound that can be prepared by a person skilled in the art based on the disclosures herein supplemented, if necessary, with relevant knowledge of the art.
- a compound such as the compounds of Formula I or other compounds herein disclosed, may be present in its free form (e.g. an amorphous form, or a crystalline form or a polymorph). Under certain conditions, compounds may also form co-forms. As used herein, the term co-form is synonymous with the term multi-component crystalline form. When one of the components in the co-form has clearly transferred or lost a proton, the resulting co-form is referred to as a "salt". The formation of a salt is determined by how large the difference is in the pKas between the partners that form the mixture.
- the term “compound” also includes a pharmaceutically acceptable salt of the compound, whether or not the phrase “pharmaceutically acceptable salt” is actually used.
- pharmaceutically acceptable salt refers to pharmaceutically acceptable organic or inorganic salts of a compound described herein.
- the pharmaceutically acceptable salts of a compound described herein are used in medicine. Salts that are not pharmaceutically acceptable may, however, be useful in the preparation of a compound described herein or of other pharmaceutically acceptable salts.
- a pharmaceutically acceptable salt involves the inclusion of another atom or molecule acting as the counter ion.
- the counter ion may be any organic or inorganic moiety that stabilizes the charge on the parent compound.
- a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. In some instances, the counter ions may be the same. In other instances, they may be different for each charged atom. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counter ions.
- salts of the compounds described herein include those derived from the reaction of the compounds described herein with inorganic or organic bases.
- the salts can be prepared in situ during the final isolation and purification of the compounds.
- the salts can be prepared from the free form of the compound described herein in a separate synthetic step.
- structures depicted herein are also meant to include all stereoisomeric (e.g., enantiomeric, diastereomeric, atropoisomeric and cis-trans isomeric) forms of the structure; for example, the R and S configurations for each asymmetric center, Ra and Sa configurations for each asymmetric axis, (Z) and (E) double bond configurations, and cis and trans conformational isomers. Therefore, single stereochemical isomers as well as racemates, and mixtures of enantiomers, diastereomers, and cis-trans isomers (double bond or conformational) of the present compounds are within the scope of the present disclosure.
- stereoisomeric e.g., enantiomeric, diastereomeric, atropoisomeric and cis-trans isomeric
- the present disclosure also embraces isotopically-labeled compounds which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses.
- Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 32 P, 33 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I, respectively.
- Certain isotopically-labeled compounds of the present invention e.g., those labeled with 3 H and 14 C are useful in compound and/or substrate tissue distribution assays.
- Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
- Positron emitting isotopes such as 15 O, 13 N, 11 C, and 18 F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy.
- Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- each instance of that substituent is chosen independently in each instance. For example, if a phenyl can be substituted with two instances of R 100 , and R 100 is selected from halogen and methyl, then that means that each instance of R 100 is separately selected from halogen or methyl; for instance, one R 100 may be fluoro and one may be methyl, or both may be chloro, etc.
- a group may be substituted with "up to" Z instances of a substituent, wherein "Z” is an integer. For instance, if “Z” is 3, then the group can be substituted with 0, 1, 2, or 3 substituents. Unless otherwise specified, each of those "Z" instances are always independently selected .
- alkyl refers to a saturated linear or branched-chain monovalent hydrocarbon radical.
- a C x alkyl is an alkyl chain containing x carbon atoms, wherein x is an integer different from 0.
- a "C x-y alkyl”, wherein x and y are two different integers, both different from 0, is an alkyl chain containing between x and y number of carbon atoms, inclusive.
- a C 1-6 alkyl is an alkyl as defined above containing any number between 1 and 6 carbon atoms.
- alkyl groups include, but are not limited to, methyl (C 1 alkyl), ethyl (C 2 alkyl), n-propyl (C 3 alkyl), isopropyl C 3 alkyl), n-butyl, isobutyl, s-butyl, t-butyl, pentyl, hexyl, heptyl, octyl and the like.
- aryl refers to a carbocyclic ring system that is aromatic and has a single point of attachment to the rest of the molecule.
- An example of an aryl ring is phenyl.
- heteroaryl refers to a ring system that is aromatic and contains one or more heteroatoms, which has a single point of attachment to the rest of the molecule.
- a heteroaryl ring is a 5 to 6-membered heteroaryl ring. In other embodiments, it is a 5-membered heteroaryl ring. In still other embodiments, it is a 6-membered heteroaryl ring.
- heteroaryl rings include, but are not limited to the following monocycles: 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-
- ring atom refers to an atom such as C, N, O or S that is part of the ring of a phenyl or a heteroaryl ring.
- a “substitutable ring atom” is a ring carbon or nitrogen atom bonded to at least one hydrogen atom. The hydrogen can be optionally replaced with a suitable substituent group. "Substitutable ring atom” does not include ring carbon or nitrogen atoms when the structure depicts that they are already attached to one or more moiety other than hydrogen and no hydrogens are available for substitution. When a certain ring, group or chain is optionally substituted, it will be understood that it may be substituted in any or some or all of its substitutable ring atoms.
- Heteroatom refers to one or more of oxygen, sulfur or nitrogen including any oxidized form of nitrogen or sulfur the quaternized form of any basic nitrogen, or a substitutable nitrogen of a heterocyclic or heteroaryl ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl).
- halogen or halo means F, Cl, Br, or I.
- haloalkyl means alkyl substituted with one or more halogen atoms.
- a C 1-3 haloalkyl could be -CFHCH 2 CHF 2 .
- fluoroalkyl means alkyl substituted with one or more fluorine atoms. This term includes perfluorinated alkyl groups, such as -CF 3 and -CF 2 CF 3 .
- alkoxy refers to an alkyl group, as previously defined, attached to the molecule, or to another chain or ring, through an oxygen atom. "Alkoxy” can be described as -O-C x-y alkyl or C x-y alkoxy.
- hydroxyl or "hydroxy” refers to -OH.
- solvent refers to an individual solvent or to a mixture of solvents that result in the desired properties of the solvent mixture.
- an "aprotic organic solvent” or “an aprotic solvent”, as defined below could be toluene, or it could be a mixture of toluene and another aprotic solvent such as DMF.
- aprotic organic solvent or aprotic solvent could also encompass a toluene/DMF mixture as long as the resulting properties of the mixture are those of an aprotic solvent.
- a protic solvent as defined below, could encompass water or a mixture of water and methanol.
- a protic solvent is a solvent that has a hydrogen atom bound to a polar group, such as oxygen (as in a hydroxyl group) or nitrogen (as in an amine group).
- a protic solvent any solvent that contains labile H+ is called a protic solvent.
- the molecules of such solvents readily donate protons (H+) to reagents.
- protic solvents cannot easily donate hydrogen.
- Protic solvents are usually polar solvents as they have high dielectric constants and high polarity.
- Aprotic solvents are usually classified as either polar aprotic or non-polar (or apolar) aprotic depending on the values of their dielectric constants.
- aprotic solvent and “aprotic organic solvent” are used interchangeably.
- protic solvents Some common characteristics of protic solvents are the ability to display hydrogen bonding, having acidic hydrogens (although they may be very weakly acidic, such as ethanol) and that they are able to dissolve salts.
- acidic hydrogens although they may be very weakly acidic, such as ethanol
- Non-limiting examples include water, most alcohols (e.g., methanol, ethanol, propanol, butanol, isopropanol, isobutanol, etc.), formic acid, hydrogen fluoride, nitromethane, acetic acid and ammonia.
- aprotic solvents Some common characteristics of aprotic solvents are that they can accept hydrogen bonds, do not have acidic hydrogen and are, only sometimes, able to dissolve salts. These criteria are relative and very qualitative. A range of acidities are recognized for aprotic solvents. Their ability to dissolve salts depends strongly on the nature of the salt.
- Polar aprotic solvents usually can dissolve salts. They lack an acidic hydrogen. Consequently, they are not hydrogen bond donors. These solvents generally have intermediate dielectric constants and polarity. Although it discourages the use of the term "polar aprotic", IUPAC describes such solvents as having both high dielectric constants and high dipole moments, an example being acetonitrile.
- solvents meeting IUPAC's criteria include N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N-methylpyrrolidone (NMP), hexamethylphosphoramide (HMPA), tetrahydrofuran, ethyl acetate, acetone, acetonitrile (MeCN), and dimethylsulfoxide (DMSO).
- DMF N,N-dimethylformamide
- DMA N,N-dimethylacetamide
- NMP N-methylpyrrolidone
- HMPA hexamethylphosphoramide
- tetrahydrofuran ethyl acetate
- MeCN acetonitrile
- DMSO dimethylsulfoxide
- Apolar or non-polar aprotic solvents usually have small dielectric constants.
- Some examples of apolar or non-polar aprotic (organic) solvents are hexane, pentane, decane and other alkanes, benzene, toluene, 1, 4-dioxane, chloroform, ethers such as diethyl ether, dichloromethane, dichloroethane, etc.
- equivalent when discussing an amount of a reagent used, refers to "molar equivalent".
- one equivalent of reagent A for each equivalent of reagent B means one mole of reagent A for each mole of reagent B is used in the reaction.
- a mole is defined as the number that results when the total weight of a substance used is divided by the molecular weight of said substance, both weights being in the same units (for example, grams).
- the compounds of the invention are defined herein by their chemical structures and/or chemical names. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.
- Some compounds of Formula I and their pharmaceutically acceptable salts are sGC stimulators that are useful for treating diseases or disorders that benefit from sGC stimulation or from an increase in the concentration of NO and/or cGMP).
- Other compounds of Formula I are useful as intermediates in the synthesis of other sGC stimulators, including other compounds of Formula I.
- a compound of Formula I the following definitions apply:
- One aspect of the invention provides a process for making a compound of Formula II, depicted below, said process comprising the steps of:
- Also disclosed is an alternative one-step process for the synthesis of a compound of Formula II comprising the direct selective de-chlorination of dichloropyrimidine (7) with hydrogen gas or a transfer hydrogenation reagent and, optionally, an appropriate amount of a suitable metal catalyst, in the presence of an appropriate amount of a suitable base, at a suitable temperature, in a suitable organic solvent, to provide mono-chloropyrimidine of Formula II.
- R 1 is an unsubstituted 5-membered heteroaryl ring, containing up to 3 heteroatoms independently selected from N, O or S.
- R 1 is isoxazolyl.
- R 1 is 3-isoxazolyl.
- R 1 is unsubstituted phenyl or 6-membered heteroaryl ring containing up to three ring nitrogen atoms.
- R 1 is a pyridine or pyrimidine.
- R 1 is phenyl.
- R 2 is a 6-membered heteroaryl optionally substituted with up to three instances of R 5 .
- R 2 is phenyl optionally substituted with up to three instances of R 5 .
- R 2 is phenyl substituted with one instance of R 5 .
- R 2 is phenyl substituted with one instance of R 5 and R 5 is halogen.
- R 2 is phenyl substituted with one instance of R 5 and R 5 is fluoro. In other embodiments, R 2 is 2-fluorophenyl. In yet other embodiments, R 2 is phenyl substituted with two instances of R 5 . In yet other embodiments, R 2 is phenyl substituted with two instances of R 5 and each instance of R 5 is independently selected from halogen. In still other embodiments, R 2 is phenyl substituted with two instances of R 5 and each instance of R 5 is fluoro.
- the one-step process for making a compound of Formula III comprises the step of coupling an appropriate amount of an amine (13) with a chloropyrimidine of Formula II, in a suitable aprotic organic solvent, optionally in the presence of an appropriate amount of a suitable base, at a suitable temperature, to yield a compound of Formula III.
- R 1 may be an unsubstituted 5-membered heteroaryl ring containing up to three ring heteroatoms independently selected from N, O or S.
- R 1 may be isoxazolyl.
- R 1 may be 3-isoxazolyl.
- R 1 may be an unsubstituted phenyl or 6-membered heteroaryl containing up to three ring nitrogen atoms.
- R 1 may be pyrimidine.
- R 1 may be pyridine.
- R 1 may be phenyl.
- R 2 may be a 6-membered heteroaryl optionally substituted with up to three instances of R 5 .
- R 2 may be phenyl optionally substituted with up to three instances of R 5 .
- R 2 may be phenyl substituted with one instance of R 5 .
- R 2 may be phenyl substituted with one instance of R 5 and R 5 is halogen.
- R 2 may be phenyl substituted with one instance of R 5 and R 5 is fluoro.
- R 2 may be 2-fluorophenyl.
- R 2 may be phenyl substituted with two instances of R 5 .
- R 2 may be phenyl substituted with two instances of R 5 and each instance of R 5 may be independently selected from halogen.
- R 2 may be phenyl substituted with two instances of R 5 and each instance of R 5 may be fluoro.
- R 6 may be hydrogen, methyl or ethyl in intermediate (13), in the compound of Formula III and in the intermediate of Formula VII.
- R 6 may be hydrogen in intermediate (13), in the compound of Formula III and in the intermediate of Formula VII.
- R 7 may be C 1-6 alkyl in intermediate (13) and the compound of Formula III and intermediate of Formula VII, and the C 1-6 alkyl may be substituted with up to 3 instances of R 8 .
- R 7 may be C 1-2 alkyl substituted with up to 3 instances of R 8 .
- R 7 may be ethyl, substituted with 3 instances of R 8 .
- one instance of R 8 may be -OH.
- One instance of R 8 may be -OH and the other two instances may independently be C 1-3 haloalkyl.
- One instance of R 8 is -OH and the other two instances may be trifluoromethyl.
- R 7 may be ethyl in intermediate (13), intermediate of Formula VII and the compound of Formula III, the; ethyl may be substituted with 3 instances of R 8 , and one of the three instances of R 8 may be -OH.
- R 7 may be ethyl substituted with 3 instances of R 8 , and one of the instances of R 8 may be -OH and the other two instances of R 8 may independently be C 1-3 haloalkyl.
- one instance of R 8 may be -OH and the other two instances of R 8 may be trifluoromethyl.
- Also disclosed herein is an alternative one-step process for the synthesis of a compound of Formula IV comprising the direct selective de-chlorinating of dichloropyrimidine (7') with hydrogen gas or a transfer hydrogenation reagent and, optionally, an appropriate amount of a suitable metal catalyst, in the presence of an appropriate amount of a suitable base, at a suitable temperature, in a suitable organic solvent, to provide the mono-chloropyrimidine of Formula IV.
- a suitable equivalent reagent to oxalyl chloride is, for instance thionyl chloride or 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC).
- An appropriate amount of oxalyl chloride or equivalent reagent is at least one equivalent of oxalyl chloride per equivalent of starting material (1) or starting material (1'). In some embodiments, an appropriate amount is between about 1 and about 3 equivalents. In other embodiments, an appropriate amount is between about 1 and about 2 equivalents. In still other embodiments, an appropriate amount is between about 1 and about 1.5 equivalents. In yet other embodiments, an appropriate amount is between about 1.1 and about 1.3 equivalents. In yet other embodiments, an appropriate amount is about 1.1 equivalents or about 1.2 equivalents.
- a suitable aprotic organic solvent is, for instance toluene.
- Other suitable solvents are, for example, methylene chloride or tetrahydrofuran.
- a suitable catalyst is DMF.
- An appropriate amount of DMF is a catalytic amount, i.e., less than one equivalent of DMF per each equivalent of starting material (1) or starting material (1'). In some embodiments, an appropriate amount is between about 0.01 and about 0.09 equivalents. In other embodiments, it is between about 0.01 and about 0.07 equivalents. In still other embodiments, it is between about 0.02 and about 0.07 equivalents. In still other embodiments it is between about 0.04 and about 0.06 equivalents.
- a suitable temperature for the reaction of starting material (1) or starting material (1') with oxalyl chloride or thionyl chloride is a temperature between about 45 °C and about 60 °C. In some embodiments, a suitable temperature is between about 45 °C and about 50 °C. In other embodiments, it is a temperature of about 50 °C.
- a suitable temperature for the reaction of starting material (1) or starting material (1') with EDAC is a temperature between about -10 °C and about 25 °C. In some embodiments, a suitable temperature is between about -10 °C and about 20 °C. In some embodiments, a suitable temperature is between about -10 °C and about 0 °C. In some embodiments, a suitable temperature is between about -10 °C and about -5 °C.
- An appropriate amount of N,O-dimethylhydroxylamine hydrochloride is at least one equivalent of N,O-dimethylhydroxylamine hydrochloride per each equivalent of starting material (1) or starting material (1'). In other embodiments, an appropriate amount of N,O-dimethylhydroxylamine hydrochloride is between about 1 equivalent and about 2 equivalents per each equivalent of starting material (1) or starting material (1'). In other embodiments, it is between about 1 equivalent and about 1.5 equivalents. In other embodiments, it is between about 1 equivalent and about 1.2 equivalents. In other embodiments, it is between about 1.1 equivalents and about 1.2 equivalents.
- a suitable base is, for instance, K 2 CO 3 or NaOH.
- Other suitable inorganic bases are, for example, NaHCO 3 , KHCO 3 , Et 3 N, or Hunig's base.
- An appropriate excess of said suitable base is at least 1.1 equivalents of base per equivalent of N,O-dimethylhydroxylamine hydrochloride used. In some embodiments, an appropriate amount is between about 1.1 and about 5 equivalents of base per equivalent of N,O-dimethylhydroxylamine hydrochloride. In some embodiments, an appropriate amount is between about 1.2 and about 5 equivalents of base per equivalent of N,O-dimethylhydroxylamine hydrochloride. In other embodiments, it is about 2 to about 3 equivalents. In still other embodiments, it is between about 2 and about 4 equivalents. In other embodiments, it is about 1.2 to about 3 equivalents. In other embodiments, it is about 1.2 to about 3 equivalents. In other embodiments, it is about 1.5 to about 3 equivalents. In other embodiments, it is about 1.2 to about 4 equivalents. In still other embodiments, it is between about 1.5 and about 4 equivalents. In other embodiments, it is about 1.2 to about 2 equivalents.
- a suitable temperature for the reaction of N,O-dimethylhydroxylamine hydrochloride and the suitable base is a temperature between about -10 °C and about 25 °C. In some embodiments, a suitable temperature is between about -10 °C and about 20 °C. In some embodiments, a suitable temperature is between about -10 °C and about 0 °C. In some embodiments, a suitable temperature is between about -10 °C and about -5 °C.
- a suitable solvent for the water/aprotic solvent mixture is, for instance, dichloromethane (DCM).
- DCM dichloromethane
- Other suitable solvents are, for example, ethyl acetate, tetrahydrofuran and 2-methyltetrahydrofuran.
- an appropriate amount of ethyl propiolate is at least one equivalent of ethyl propiolate per equivalent of intermediate (2) or intermediate (2').
- an appropriate amount of ethyl propiolate is between about 1 and about 2 equivalents. In other embodiments, it is between about 1 and about 1.8 equivalents. In other embodiments, it is between about 1 and about 1.6 equivalents. In still other embodiments, it is between about 1.1 and about 1.5 equivalents. In yet other embodiments, it is about 1.1 equivalents. In still other embodiments, it is about 1.5 equivalents.
- a suitable aprotic organic solvent is an anhydrous organic solvent.
- a suitable solvent is anhydrous tetrahydrofuran (THF).
- THF tetrahydrofuran
- Other suitable solvents in this step are, for example, 2-methyltetrahydrofuran and toluene.
- a suitable temperature is a temperature of about -75 °C to about -30 °C. In some embodiments, a suitable temperature is one between about -70 °C to about -50 °C. In some embodiments, a suitable temperature is between about -65 °C to about -50 °C. In other embodiments, a suitable temperature is between about -65 °C to about -55 °C. In still other embodiments, a suitable temperature is between about -70 °C to about -60 °C.
- a suitable base is, for instance, sodium bis(trimethylsilyl)amide (NaHMDS).
- Other suitable bases are, for instance, lithium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide and lithium diisopropylamide.
- An appropriate amount of a suitable base is between about 1 equivalent and about 1.65 equivalents per each equivalent of intermediate (2) or intermediate (2'). In some embodiments, it is between about 1 equivalent and about 1.5 equivalents. In some embodiments, it is between about 1 equivalent and about 1.3 equivalents. In other embodiments, it is between about 1.1 equivalents and about 1.65 equivalents. In other embodiments, it is between about 1.1 equivalents and about 1.5 equivalents. In still other embodiments, it is between about 1.1 equivalents and about 1.4 equivalents. In yet other embodiments it is between 1.1 equivalents and about 1.3 equivalents.
- an appropriate amount of hydrazine is at least one equivalent of hydrazine per each equivalent of intermediate (3) or intermediate (3'). In some embodiments, an appropriate amount of hydrazine is between about 1 equivalent and about 2 equivalents. In other embodiments, it is between about 1 equivalent and about 1.5 equivalent. In still other embodiments, it is between about 1 equivalent and about 1.3 equivalents. In still other embodiments, it is between about 1.1 equivalents and about 1.4 equivalents. In still other embodiments it is between 1.1 equivalents and about 1.3 equivalents.
- An optional suitable base is, for instance, potassium carbonate (K 2 CO 3 ).
- Other optional suitable organic bases in this step are, for example, sodium acetate (NaOAc), sodium carbonate (Na 2 CO 3 ), sodium hydrogen carbonate (NaHCO 3 ) and potassium bicarbonate (KHCO 3 ).
- An appropriate amount of a suitable base is an amount that will neutralize the acid from the hydrazine hydrochloride, when the hydrochloride form of the hydrazine is used. For instance, about 0.5 to about 1.1 equivalents of base per each equivalent of hydrazine hydrochloride. In other embodiments, an appropriate amount is about 0.5 to about 0.9 equivalents. In still other embodiments, it is about 0.65 equivalents.
- a suitable protic solvent is, for instance, absolute ethanol or isopropanol.
- Other solvents that may be used in this step are, for example dichloromethane, isopropanol and methanol.
- a suitable temperature is between about 0 °C and about 40 °C. In other embodiments, a suitable temperature is between about 0 °C and about 30 °C. In some embodiments, it is between about 0 °C and about 25 °C. In other embodiments, it is between about 0 °C and about 15 °C. In other embodiments, it is between about 0 °C and about 10 °C. In still other embodiments, it is between about 10 °C and about 25 °C.
- An appropriate amount of ammonium chloride is between about 2.5 and about 6 equivalents of ammonium chloride for each equivalent of intermediate (4) or intermediate (4'). In some embodiments, an appropriate amount is between about 2.5 and about 5.5 equivalents. In some embodiments, an appropriate amount is between about 3.5 and about 4 equivalents. In other embodiments, an appropriate amount is about 3.8 equivalents. In still other embodiments, an appropriate amount is about 3.5 equivalents. In some embodiments, an appropriate amount is between about 4.5 equivalents and 5.0 equivalents. In other embodiments, an appropriate amount is about 4.8 equivalents.
- An appropriate amount of trimethylaluminum is between about 2.5 and about 5.5 equivalents of trimethylaluminum for each equivalent of intermediate (4) or intermediate (4'). In some embodiments, an appropriate amount is between about 3.5 and about 5.5 equivalents. In other embodiments, an appropriate amount is between about 3.5 and about 4.5 equivalents. In other embodiments, an appropriate amount is between about 3.5 and about 4 equivalents. In other embodiments, an appropriate amount is about 3.5 equivalents.
- a suitable aprotic organic solvent is, for instance, toluene.
- Other suitable solvents are, for example, xylene.
- a suitable temperature for toluene is between about 60 °C and about 115 °C. In some embodiments, a suitable temperature is between about 70 °C and about 110 °C. In other embodiments, it is between about 70 °C and about 110 °C. In still other embodiments, it is between about between about 80 °C and about 110 °C. In still other embodiments, it is between about 90 °C and about 110 °C.
- a suitable temperature for xylene is between about 70 °C and about 130 °C.
- a suitable aqueous mineral acid is concentrated HCl, for instance 3 N HCl or 37 % by weight HCl.
- Other suitable mineral acids that can be used to induce the precipitation of the intermediate (4) or intermediate (4') are, for instance, H 2 SO 4 .
- An appropriate amount of fluoromalonate is at least one equivalent of fluoromalonate per each equivalent of intermediate (5A) or (5B) or intermediate (5'A) or (5'B). In some embodiments, it is between about 1 equivalent and about 2 equivalents of fluoromalonate. In still other embodiments, it is between about 1.2 equivalents and about 2 equivalents. In still other embodiments, it is between about 1.3 and about 1.9 equivalents. In other embodiments, it is between 1.4 and 1.6 equivalents. In other embodiments, it is between about 1.7 and 1.9 equivalents.
- a suitable base is, for instance, sodium methoxide (NaOMe).
- NaOMe sodium methoxide
- MeOH a solution in MeOH.
- a 23 % wt solution in MeOH can be used.
- 30 % wt solution in MeOH can be used.
- a 5.4 M solution in MeOH could be used.
- Other bases that could be used in this step include EtONa.
- An appropriate amount of a suitable base is an excess with respect to the amount of intermediate (5A) or (5B) or intermediate (5'A) or (5'B). In some embodiments, an appropriate amount is between about 3 and about 10 equivalents of NaOMe per each equivalent of intermediate (5A) or (5B) or intermediate (5'A) or (5'B). In other embodiments, an appropriate amount is between about 3 and about 6 equivalents. In still other embodiments, it is between about 3 and about 5 equivalents. In still other embodiments, it is between about 4 and about 5 equivalents. In yet other embodiments, an appropriate amount is about 4.5 equivalents.
- a suitable protic solvent is, for example, MeOH.
- Other suitable solvents that could be used in this step include EtOH.
- a suitable temperature is between about 10 °C and about 40 °C. In some embodiments, a suitable temperature is between about 15 °C and about 35 °C. In other embodiments, a suitable temperature is between about 15 °C and about 30 °C. In other embodiments, a suitable temperature is between about 20 °C and about 35 °C. In still other embodiments, a suitable temperature is between about 20 °C and about 30 °C.
- a suitable mineral acid is, for example, 1.5 N HCl.
- Other suitable mineral acids that could be used in this step include sulfuric acid.
- An appropriate amount of a mineral acid is at least an excess with respect to the amount of the suitable base used.
- an appropriate amount is at least one equivalent of mineral acid per each equivalent of base used (e.g., NaOMe).
- an appropriate amount is about 1.1 equivalents of mineral acid per each equivalent of base.
- an appropriate amount of mineral acid is between about 4.5 and about 5.5 equivalents of mineral acid per each equivalent of intermediate (5B) or intermediate (5'B).
- an appropriate amount of mineral acid is between about 4.7 and about 5.0 equivalents. In still other embodiments, it is about 4.9 equivalents.
- An appropriate amount of POCl 3 is at least two equivalents of POCl 3 per each equivalent of intermediate (6) or intermediate (6') used. In some embodiments, an appropriate amount of POCl 3 is at least 4 equivalents. In some embodiments, an appropriate amount is at least 5 equivalents. In still other embodiments, an appropriate amount is about 6 equivalents of POCl 3 per each equivalent of intermediate (6) or intermediate (6').
- a suitable temperature is between about 60 °C and about 90 °C. In some embodiments, a suitable temperature is between about 65 °C and about 90 °C. In other embodiments, a suitable temperature is between about 70 °C and about 90 °C. In still other embodiments, a suitable temperature is between about 75 °C and about 90 °C. In yet other embodiments, a suitable temperature is between about 70 °C and about 80 °C.
- a suitable aprotic organic solvent is, for instance, acetonitrile (CNMe).
- CCMe acetonitrile
- a suitable optional base is, for instance, N,N -dimethylaniline.
- the reaction also works in the absence of a base.
- An appropriate amount of a suitable base is between about 0.2 and about 2 equivalents of base per each equivalent of intermediate (6) or intermediate (6') used. In some embodiments, an appropriate amount of base is between about 1.5 and about 1.8 equivalents. In other embodiments, it is between about 0.8 equivalents and about 1.2 equivalents. In still other embodiments, it is about 1 equivalent.
- an appropriate amount of sodium methoxide is about 1 equivalent of NaOMe per each equivalent of intermediate (7) or intermediate (7').
- an appropriate amount of NaOMe is a slight excess of NaOMe per each equivalent of intermediate (7) or intermediate (7').
- an appropriate amount of NaOMe is between 1.1 and 1.3 equivalents per each equivalent of intermediate (7) or intermediate (7'). In other embodiments, an appropriate amount is about 1.2 equivalents.
- a suitable temperature is between about 15 °C and about 30 °C. In some embodiments, a suitable temperature is between about 20 °C and about 30 °C. In other embodiments, it is between about 15 °C and about 28 °C. In other embodiments, between about 20 °C and about 28 °C. In still other embodiments, between about 23 °C and about 27 °C.
- a suitable protic solvent is, for instance, methanol (MeOH).
- a suitable transfer hydrogenation reagent is HCOOH.
- HCOOH was most commonly used in the presence of organic/inorganic bases such as Et 3 N, NaOH, NaHCO 3 , etc.
- a suitable metal catalyst is palladium on activated carbon, for instance 10 % Pd on activated carbon.
- An appropriate amount of a suitable metal catalyst is a catalytic amount, i.e., less than one equivalent of Pd per equivalent of intermediate (8) or intermediate (8'). In some embodiments, an appropriate amount of the suitable metal catalyst is between 0.01 and 0.03 equivalents of Pd per equivalent of intermediate (8) or intermediate (8'). In other embodiments, an appropriate amount of the suitable metal catalyst is between 0.01 and 0.025 equivalents of Pd per equivalent of intermediate (8) or intermediate (8'). In still other embodiments, an appropriate amount of the suitable metal catalyst is between 0.015 and 0.025 equivalents of Pd per equivalent of intermediate (8) or intermediate (8'). In yet other embodiments, an appropriate amount of the suitable metal catalyst is between 0.01 and 0.02 equivalents of Pd per equivalent of intermediate (8) or intermediate (8').
- a suitable base is triethylamine (Et 3 N).
- Other suitable bases that can be used are, for example, Hunig's base, NaHCOs, KHCO 3 , and sodium acetate.
- An appropriate amount of a suitable base is at least one equivalent of base per each equivalent of intermediate (8) or intermediate (8'). In some embodiments, a suitable amount of base is at least 1.5 equivalents. In other embodiments, it is about 1.6 equivalents.
- a suitable temperature is between about 35 °C and about 60 °C.
- a suitable temperature is between about 35 °C and about 55 °C. In some embodiments, a suitable temperature is between about 40 °C and about 50 °C.
- a suitable organic solvent is, for example, THF.
- Other solvents that can be used are, for instance methanol, ethanol, isopropanol, 2-methyl-tetrahydrofuran or mixtures thereof.
- a suitable aqueous acid is HCl.
- Other acids that could be used include, for instance, methylsulfonic acid (MeSOsH) or HBr.
- An appropriate amount of acid is between about 3 and about 6 equivalents. In some embodiments, an appropriate amount is between about 4 and about 6 equivalents. In other embodiments, it is between about 4.5 equivalents and about 6 equivalents. In still other embodiments, it is about 4.90 to about 5 equivalents.
- HCl can be provided, for instance, in the form of concentrated HCl (e.g., 37 wt % HCl).
- a suitable protic solvent is, for instance, MeOH.
- Other suitable protic solvents are EtOH and iPrOH.
- a suitable temperature is between about 50 °C and about 70 °C. In some embodiments, a suitable temperature is between about 55 °C and about 65 °C. In still other embodiments, a suitable temperature is between about 60 °C and about 65 °C. In still other embodiments, a suitable temperature is between about 62 °C and about 65 °C.
- An appropriate amount of POCl 3 is at least two equivalents of POCl 3 per each equivalent of intermediate (10) or intermediate (10') used. In some embodiments, an appropriate amount of POCl 3 is at least 4 equivalents. In some embodiments, an appropriate amount is at least 3 equivalents. In some embodiments, an appropriate amount is at least 2 equivalents. In some embodiments, an appropriate amount is at least 1 equivalent. In still other embodiments, an appropriate amount is between about 1 and about 4 equivalents of POCl 3 per each equivalent of intermediate (10) or intermediate (10').
- a suitable temperature is between about 50 °C and about 90 °C. In some embodiments, a suitable temperature is between about 60 °C and about 90 °C. In some embodiments, a suitable temperature is between about 65 °C and about 90 °C. In other embodiments, a suitable temperature is between about 70 °C and about 90 °C. In still other embodiments, a suitable temperature is between about 75 °C and about 90 °C. In yet other embodiments, a suitable temperature is between about 75 °C and about 85 °C. In other embodiments, a suitable temperature is between about 75 °C and about 80 °C.
- a suitable aprotic solvent is, for instance, acetonitrile (CNMe).
- CCMe acetonitrile
- a suitable optional base is, for instance, N,N -dimethylaniline.
- the reaction also works in the absence of a base.
- An appropriate amount of a suitable base is between about 0.2 and about 2 equivalents of base per each equivalent of intermediate (10) or intermediate (10') used. In some embodiments, an appropriate amount of base is between about 1.3 and about 1.6 equivalents. In some embodiments, an appropriate amount of base is between about 1.2 and about 1.8 equivalents. In other embodiments, it is about 1 equivalent.
- An appropriate amount of sodium hydroxide (NaOH) is between about 2 and about 2.5 equivalents of NaOH per each equivalent of intermediate (7) or intermediate (7'). In other embodiments, an appropriate amount is about 2.2 equivalents.
- a suitable temperature is between about 45 °C and about 70 °C. In some embodiments, a suitable temperature is between about 50 °C and about 65 °C. In other embodiments, it is between about 55 °C and about 60 °C.
- phase transfer catalyst is tetrabutylammonium hydroxide.
- suitable phase transfer catalysts that could be used comprise benzyltrimethylammonium chloride, benzyltriethylammonium chloride, methyltricaprylammonium chloride, methyltributylammonium chloride, and methyltrioctylammonium chloride.
- An appropriate amount of a suitable phase transfer catalyst is a catalytic amount, i.e., less than one equivalent of phase transfer catalyst per equivalent of intermediate (7) or intermediate (7').
- a catalytic amount is between about 0.1 and about 0.5 equivalents. In other embodiments, it is between about 0.1 and about 2.5 equivalents. In still other embodiments, it is between about 0.1 and about 0.15 equivalents.
- a suitable protic solvent is, for instance, water.
- a suitable aprotic solvent is, for example, tetrahydrofuran.
- a suitable transfer hydrogenation reagent is HCOOH.
- HCOOH was most commonly used in the presence of organic/inorganic bases such as Et 3 N, NaOH, NaHCO 3 , etc.
- a suitable metal catalyst is palladium on activated carbon, for instance 10 % Pd on activated carbon.
- An appropriate amount of a suitable metal catalyst is a catalytic amount, i.e., less than one equivalent of Pd per equivalent of intermediate (8B) or intermediate (8'B). In some embodiments, an appropriate amount of the suitable metal catalyst is between 0.01 and 0.02 equivalents of Pd per equivalent of intermediate (8B) or intermediate (8'B).
- a suitable base is triethylamine (Et 3 N).
- Other suitable bases that can be used are, for example, Hunig's base, NaHCOs, KHCO 3 , and sodium acetate.
- An appropriate amount of a suitable base is at least one equivalent of base per each equivalent of intermediate (8B) or intermediate (8'B). In some embodiments, a suitable amount of base is at least 1.5 equivalents. In other embodiments, it is about 1.6 equivalents.
- a suitable temperature is between about 15 °C and about 60 °C. In some embodiments, a suitable temperature is between about 15 °C and about 55 °C. In some embodiments, a suitable temperature is between about 35 °C and about 55 °C. In other embodiments, a suitable temperature is between about 40 °C and about 50 °C. In still other embodiments, a suitable temperature is between about 15 °C and about 25 °C. In yet other embodiments, a suitable temperature is between about 20 °C and about 30 °C. In still other embodiments, a suitable temperature is between about 20 °C and about 25 °C.
- a suitable organic solvent is, for example, THF.
- Other solvents that can be used are, for instance methanol, ethanol, isopropanol, 2-methyl-tetrahydrofuran or mixtures thereof.
- An appropriate amount of POCl 3 is at least two equivalents of POCl 3 per each equivalent of intermediate (10) or intermediate (10') used. In some embodiments, an appropriate amount of POCl 3 is at least 4 equivalents. In some embodiments, an appropriate amount is at least 3 equivalents. In some embodiments, an appropriate amount is at least 2 equivalents. In some embodiments, an appropriate amount is at least 1 equivalent. In still other embodiments, an appropriate amount is between about 1 and about 4 equivalents of POCl 3 per each equivalent of intermediate (10) or intermediate (10').
- a suitable temperature is between about 50 °C and about 80 °C. In some embodiments, a suitable temperature is between about 60 °C and about 80 °C. In some embodiments, a suitable temperature is between about 65 °C and about 80 °C. In other embodiments, a suitable temperature is between about 70 °C and about 80 °C. In still other embodiments, a suitable temperature is between about 75 °C and about 80 °C.
- a suitable aprotic solvent is, for instance, acetonitrile (CNMe).
- CCMe acetonitrile
- a suitable optional base is, for instance, N,N -dimethylaniline.
- the reaction also works in the absence of a base.
- An appropriate amount of a suitable base is between about 0.2 and about 2 equivalents of base per each equivalent of intermediate (10) or intermediate (10') used. In some embodiments, an appropriate amount of base is between about 1.3 and about 1.6 equivalents. In some embodiments, an appropriate amount of base is between about 1.2 and about 1.8 equivalents. In other embodiments, it is about 1 equivalent.
- a suitable transfer hydrogenation reagent is HCOOH.
- HCOOH was most commonly used in the presence of organic/inorganic bases such as Et 3 N, NaOH, NaHCO 3 , etc.
- a suitable metal catalyst is palladium on activated carbon, for instance 10 % Pd on activated carbon.
- An appropriate amount of a suitable metal catalyst is a catalytic amount, i.e., less than one equivalent of Pd per equivalent of intermediate (7) or intermediate (7'). In some embodiments, an appropriate amount of the suitable metal catalyst is between 0.01 and 0.02 equivalents of Pd per equivalent of intermediate (7) or intermediate (7').
- a suitable base is triethylamine (Et 3 N).
- Other suitable bases that can be used are, for example, Hunig's base, NaHCOs, KHCO 3 , and sodium acetate.
- An appropriate amount of a suitable base is at least one equivalent of base per each equivalent of intermediate (7) or intermediate (7'). In some embodiments, a suitable amount of base is at least 1.5 equivalents. In other embodiments, it is about 1.6 equivalents.
- a suitable temperature is between about 35 °C and about 60 °C.
- a suitable temperature is between about 35 °C and about 55 °C. In some embodiments, a suitable temperature is between about 40 °C and about 50 °C.
- a suitable organic solvent is, for example, THF.
- Other solvents that can be used are, for instance methanol, ethanol, isopropanol, 2-methyl-tetrahydrofuran or mixtures thereof.
- Also disclosed herein is a one-step process for making a compound of Formula V.
- the one-step process for making a compound of Formula V comprises coupling an appropriate amount of an amine (13) with a chloropyrimidine of Formula IV, optionally in the presence of an appropriate amount of a suitable base, in a suitable aprotic organic solvent, at a suitable temperature, to yield a compound of Formula V.
- R 6 may be hydrogen, methyl or ethyl in intermediate (13), the compound of Formula V and the intermediate of Formula VIII.
- R 6 may be hydrogen in intermediate (13), the compound of Formula V and the intermediate of Formula VIII.
- R 7 may be C 1-6 alkyl in intermediate (13), intermediate of Formula VIII and the compound of Formula V, and the C 1-6 alkyl may be substituted with up to 3 instances of R 8 .
- R 7 may be C 1-2 alkyl, substituted with up to 3 instances of R 8 .
- R 7 may be ethyl, substituted with 3 instances of R 8 .
- one instance of R 8 may be -OH.
- One instance of R 8 may be -OH and the other two instances may independently be selected from C 1-3 haloalkyl.
- One instance of R 8 may be -OH and the other two instances may be trifluoromethyl.
- R 7 may be ethyl in intermediate (13), intermediate of Formula VIII and the compound of Formula V, the ethyl may be substituted with 3 instances of R 8 , and one of the three instances of R 8 may be -OH.
- R 7 may be ethyl, substituted with 3 instances of R 8 , and one of the instances of R 8 is -OH and the other two instances of R 8 may be independently selected from C 1-3 haloalkyl.
- one instance of R 8 is -OH and the other two instances of R 8 may be trifluoromethyl.
- Also disclosed herein is a one-step process for making a compound of Formula VI.
- the one-step process for making a compound of Formula VI comprises coupling an appropriate amount of an amine (14) with a chloropyrimidine of Formula II, optionally in the presence of an appropriate amount of a suitable base, in a suitable aprotic organic solvent, at a suitable temperature, to yield a compound of Formula VI.
- Also disclosed herein is another process for making a compound of Formula VI.
- This process for making a compound of Formula VI comprises the steps of:
- R 1 may be an unsubstituted 5-membered heteroaryl ring containing up to three ring heteroatoms independently selected from N, O or S.
- R 1 may be isoxazolyl.
- R 1 may be 3-isoxazolyl.
- R 1 may be an unsubstituted phenyl or 6-membered heteroaryl ring containing up to three ring nitrogen atoms.
- R 1 may be phenyl.
- R 2 may be a 6-membered heteroaryl optionally substituted with up to three instances of R 5 .
- R 2 may be phenyl optionally substituted with up to three instances of R 5 .
- R 2 may be phenyl substituted with one instance of R 5 .
- R 2 may be phenyl substituted with one instance of R 5 and R 5 is halogen.
- R 2 may be phenyl substituted with one instance of R 5 and R 5 is fluoro.
- R 2 may be 2-fluorophenyl.
- R 2 may be phenyl substituted with two instances of R 5 .
- R 2 may be phenyl substituted with two instances of R 5 and each instance of R 5 is independently halogen.
- R 2 may be phenyl substituted with two instances of R 5 and each instance of R 5 may be fluoro.
- Compound I (1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimi din-4-yl)amino)methyl)propan-2-ol).
- Compound I has the structure depicted below.
- Compound I is an sGC stimulator that has demonstrated efficacy for the treatment of a number of NO related disorders in preclinical models.
- the one-step process for making Compound I comprises coupling an appropriate amount of an amine (14) with a chloropyrimidine of Formula IV in a suitable aprotic organic solvent, optionally in the presence of an appropriate amount of a suitable base, at a suitable temperature, to yield Compound I.
- An appropriate amount of amine (13) or amine (14) is at least one equivalent of amine (13) or amine (14) per each equivalent of compound of Formula II or compound of Formula IV.
- An excess of amine (13) or amine (14) may be used.
- An amount between about 1 and about 5 equivalents of the amine (13) or amine (14) can be used.
- the appropriate amount may be between about 1 and about 4 equivalents. It may be between about 1 and about 3 equivalents.
- a suitable optional base is, for instance, Hunig's base.
- Other suitable optional bases are, for example, Et 3 N, NaHCOs, and KHCO 3 .
- Amine (13) or amine (14) itself may also be used as the base.
- An appropriate amount of a suitable base is at least one equivalent of optional base per each equivalent of intermediate of Formula II or intermediate of Formula IV. In some embodiments, an appropriate amount is about 2 equivalents.
- a suitable aprotic organic solvent is dimethylsulfoxide (DMSO).
- DMSO dimethylsulfoxide
- Other suitable aprotic organic solvents are, for instance, N,N -dimethylformamide (DMF), N,N -dimethylacetamide (DMA), and tert -butanol (t-BuOH).
- a suitable temperature is between about 100 °C and about 135 °C.
- a suitable temperature may be between about 120 °C and about 130 °C.
- a suitable temperature may be between about 125 °C and about 130 °C.
- Also disclosed is another process for making Compound I comprises the steps of:
- An appropriate amount of ammonium hydroxide is at least 3 equivalents of ammonium hydroxide for each equivalent of intermediate (12).
- An appropriate amount may be between about 3 equivalents and about 12 equivalents. In other embodiments, it may be between about 4 equivalents and about 10 equivalents. It may be between about 6 equivalents and about 12 equivalents. It may be between about 8 equivalents and about 10 equivalents. It may be about 10 equivalents.
- a suitable aprotic organic solvent is, for example, a dialkyl ether.
- the ether may be methyl t-butyl ether.
- Other ethers that may be use include, for instance, diisopropyl ether.
- Other aprotic organic solvents that may be used are, for example, dichloromethane and ethyl acetate.
- a suitable temperature is between about 15 °C and about 35 °C.
- a suitable temperature may be between about 20 °C and about 30 °C.
- a suitable temperature may be between about 23 °C and about 28 °C.
- an appropriate amount of an amine (14) is at least one equivalent of amine (14) per each equivalent of compound of Formula II or compound of Formula IV.
- An excess of amine (14) may be used.
- An amount between about 1 and about 5 equivalents of amine (14) can be used.
- the appropriate amount may be between about 1 and about 4 equivalents. It may be between about 1 and about 3 equivalents.
- a suitable optional base is, for instance, Hunig's base.
- Other suitable optional bases are, for example, Et 3 N, NaHCOs, and KHCO 3 .
- Amine (14) itself may also be used as the base.
- An appropriate amount of a suitable base is at least one equivalent of optional base per each equivalent of intermediate of Formula II or intermediate of Formula IV.
- An appropriate amount may be about 2 equivalents.
- a suitable aprotic organic solvent is dimethylsulfoxide (DMSO).
- DMSO dimethylsulfoxide
- Other suitable aprotic organic solvents are, for instance DMF, DMA, and t-BuOH.
- a suitable temperature is between about 100 °C and about 135 °C.
- a suitable temperature may be between about 120 °C and about 130 °C.
- a suitable temperature may be between about 125 °C and about 130 °C.
- An appropriate amount of amine (13) or amine (14) is at least one equivalent of amine (13) or amine (14) per each equivalent of intermediate (7) or intermediate (7').
- An excess of amine (13) or amine (14) may be used.
- An amount between about 1 and about 3 equivalents of the amine (13) or amine (14) can be used.
- the appropriate amount may be between about 1 and about 2.9 equivalents. It may be between about 1 and about 2.7 equivalents. It may be about 2.6 equivalents.
- a suitable optional base is, for instance, Hunig's base.
- Other suitable optional bases are, for example, Et 3 N, NaHCOs, and KHCO 3 .
- Amine (13) or amine (14) itself may also be used as the base, when used in excess.
- An appropriate amount of a suitable base is at least one equivalent of optional base per each equivalent of intermediate (7) or intermediate (7'). An appropriate amount may be about 2 equivalents.
- a suitable aprotic organic solvent is dimethylsulfoxide (DMSO).
- DMSO dimethylsulfoxide
- Other suitable aprotic organic solvents are, for instance, N,N -dimethylformamide (DMF), N,N -dimethylacetamide (DMA), and tert -butanol (t-BuOH).
- a suitable temperature is between about 50 °C and about 90 °C.
- a suitable temperature may be between about 55 °C and about 65 °C.
- Asuitable temperature may be between about 75 °C and about 90 °C.
- a suitable temperature may be between about 55 °C and about 85 °C.
- a suitable temperature may be between about 75 °C and about 85 °C.
- a suitable temperature may be between about 50 °C and about 70 °C.
- a suitable transfer hydrogenation reagent is HCOOH.
- HCOOH was most commonly used in the presence of organic/inorganic bases such as Et 3 N, NaOH, NaHCO 3 , etc.
- a suitable metal catalyst is palladium on activated carbon, for instance 10 % Pd on activated carbon.
- An appropriate amount of a suitable metal catalyst is a catalytic amount, i.e., less than one equivalent of Pd per equivalent of intermediate of Formula VII, Formula VIII, Formula IX or Formula X. In some embodiments, an appropriate amount of the suitable metal catalyst is between 0.01 and 0.02 equivalents of Pd per equivalent of intermediate of Formula VII, Formula VIII, Formula IX or Formula X.
- a suitable base is triethylamine (Et 3 N).
- Other suitable bases that can be used are, for example, Hunig's base, NaHCOs, KHCO 3 , and sodium acetate.
- An appropriate amount of a suitable base is at least one equivalent of base per each equivalent of intermediate of Formula VII, Formula VIII, Formula IX or Formula X.
- a suitable amount of base is at least 1.5 equivalents. It may be about 1.6 equivalents.
- a suitable temperature is between about 35 °C and about 60 °C.
- a suitable temperature is between about 35 °C and about 55 °C.
- a suitable temperature may be between about 40 °C and about 50 °C.
- a suitable organic solvent is, for example, THF.
- Other solvents that can be used are, for instance methanol, ethanol, isopropanol, 2-methyl-tetrahydrofuran or mixtures thereof.
- the processes described herein have the advantage of allowing preparation of sGC stimulators and intermediates of Formula I in high yield and purity.
- the present invention has the additional advantage of facile reaction conditions that are readily scaled up for large scale manufacturing.
- the compound of Formula I is a compound of Formula II.
- the compound of Formula I is a compound of Formula IV.
- the compound of Formula I is a compound of Formula III.
- it is a compound of Formula V.
- the compound of Formula I is a compound of Formula VI.
- the compound of Formula I is a Compound I (1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimi din-4-yl)amino)methyl)propan-2-ol).
- intermediates (4) and (4') may be carried out in two steps.
- the first step involves reaction of a ketone (19) with diethyloxalate to provide an intermediate (20).
- intermediate (20) is reacted with a suitably substituted hydrazine or its corresponding hydrochloride salt.
- the hydrazine would be one of Formula NH 2 NH-CH 2 -(2-fluorophenyl).
- This process is advantageous over alternative processes to generate compounds of Formula III, Formula V, Formula VI and Compound I in that it uses the symmetrical intermediate (7) or (7') as the starting material.
- This symmetrical intermediate generated from symmetrical intermediates (6) and (6'), as discussed above, results in overall high yields and purities of the subsequent steps.
- Two high yielding steps yield the final Formula V amine.
- the overall process is amenable to scale-up for large scale manufacturing.
- a method or device that "comprises”, “has”, “includes” or “contains” one or more steps or elements possesses those one or more steps or elements, but is not limited to possessing only those one or more steps or elements.
- a step of a method or an element of a device that "comprises”, “has”, “includes” or “contains” one or more features possesses those one or more features, but is not limited to possessing only those one or more features.
- a device or structure that is configured in a certain way is configured in at least that way, but may also be configured in ways that are not listed.
- each range is intended to be a shorthand format for presenting information, where the range is understood to encompass each discrete point within the range as if the same were fully set forth herein.
- Time Table Time (minute) % Solvent A % Solvent B 0 85 15 10 5 95 15 5 95 Retention Times of selected compounds: Compound Approximate Retention Time (Min) Isooxazole-3-carboxylic acid (1') 1.8 Compound (2') 3.1 Compound (3') 6.2 Compound (4') 8.6 Compound (5') 5.1 Compound (6') 6.2 Compound (7') 10.3 Compound (8') 10.0 Compound (9') 8.8 Compound (10') 7.0 Formula IV 9.3 Compound I 8.9
- Isooxazole-3-carboxylic acid ((1'), 241.6 g, 2137 mmoles, 1.0 equiv.), toluene (1450 mL) and DMF (7.8 g, 107 mmoles, 0.05 equiv.) were charged to a suitable reaction vessel equipped with a mechanical stirrer and a digital thermometer. The resulting slurry was heated to 45-50 °C. Oxalyl chloride (325 g, 2559 mmoles, 1.2 equiv.) was then charged via an addition funnel over the course of 2 h while maintaining the reaction temperature between 45 to 50 °C and a vigorous gas evolution was observed. A brown mixture was obtained after addition.
- the brown mixture was heated to 87 to 92 °C over 1 h and stirred at 87 to 92 °C for 1 h.
- the reaction was completed as shown by HPLC. During heating, the brown mixture turned into a dark solution.
- the reaction was monitored by quenching a portion of the reaction mixture into piperidine and monitoring the piperidine amide by HPLC.
- the dark mixture was cooled to 20-25 °C and then filtered through a sintered glass funnel to remove any insolubles. The dark filtrate was concentrated under reduced pressure to a volume of 400 mL dark oil.
- the dark oil was dissolved in a solution of dichloromethane/ethyl acetate/heptane (150mL/100mL/100mL). The solution was loaded on a silica pad (410 g) and the silica pad was eluted with ethyl acetate/heptane (1/1 v/v). The filtrate ( ⁇ 3000 mL) was collected and then concentrated under reduced pressure to a volume of 150 mL to give a slurry upon standing. Heptane (200 mL) was then added to the slurry and the slurry was concentrated under reduced pressure to a volume of 150 mL.
- Anhydrous ammonium chloride (267 g, 4991 mmoles, 5.0 equiv.) and toluene (5400 mL) were charged to a suitable reaction vessel equipped with a mechanical stirrer and a digital thermometer.
- Trimethylaluminum in toluene (2 M, 2400 mL, 4800 mmoles, 4.8 equiv.) was charged slowly via an addition funnel while maintaining the reaction temperature at 20 to 40 °C (Note: Methane gas evolution was observed during addition). Then the mixture was heated to 75 to 80 °C over 30 min. and a clear white solution was obtained.
- the mixture was stirred at 20 to 26 °C over 3 h after addition.
- the mixture was allowed to separate and the bottom aqueous layer was extracted with methyl t-butyl ether (2 ⁇ 354 mL).
- the combined organic layers were concentrated under reduced pressure to bring the volume to 303 mL.
- Methyl t-butyl ether (354 mL) was added and the mixture was concentrated under reduced pressure to bring the volume to 303 mL.
- Heptane (303 mL) was added and the mixture was concentrated under reduced pressure to bring the volume to 303 mL.
- the slurry was filtered and the filter cake was washed with heptane (100 mL).
- the organic layer was washed with a saturated sodium bicarbonate solution (1000 mL) and with 1 N HCl solution (1000 mL) and then concentrated under reduced pressure to a volume of 1500 mL.
- the organic solution was loaded on a silica pad (800 g) and the silica pad was eluted with methyl t-butyl ether.
- the clean fractions were collected and concentrated under reduced pressure to a volume of 2000 mL.
- the MTBE solution was heated at 45 to 55 °C and heptane (2000 mL) was charged via an addition funnel over 30 min while maintaining the reaction temperature between 45 to 55 °C to obtain a slurry.
- the slurry was cooled to 20 to 25 °C and stirred at 20 to 25 °C over 30 min.
- the resulting slurry was filtered, and the filter cake was washed with a pre-mixed solution of MTBE and heptane (400 mL/600 mL).
- the filter cake was then dried under vacuum at 45 to 55 °C over 5 hr to furnish Compound I as an off-white solid (130 g, 68% yield, >99% pure by HPLC).
- Isooxazole-3-carboxylic acid ((1'), 3.857 kg, 34.1 moles, 1.0 equiv.), toluene (19.3 L) and DMF (0.131 L, 1.692 moles, 0.05 equiv.) were mixed in a 30 L jacketed reaction vessel equipped with nitrogen inlet-outlet, overhead stirrer, a thermocouple and an addition funnel. The resulting slurry was heated to 45 to 55 °C. Oxalyl chloride (4.8 kg, 37.8 moles, 1.11 equiv.) was then charged via an addition funnel over the course of 4 h 30 min. while maintaining the reaction temperature between 45 to 55 °C and a vigorous gas evolution was observed. A brown mixture was obtained after the addition.
- the brown mixture was held at 45 to 55 °C for 30 min. and then heated to 85 to 95 °C and stirred at 85 to 95 °C for 1 h. During heating, the brown mixture turned into a dark mixture. The dark mixture was slowly cooled to 20 to 25 °C over the course of 4 h and the reaction was monitored by quenching a portion of the reaction mixture into piperidine and monitoring the disappearance of the piperidine amide by HPLC until the area /area % of (1'): piperidine amide was ⁇ 1.9). After the reaction was complete by HPLC the dark mixture was in-line filtered to 20 L rotavapor flask.
- Toluene (3.9 L) was used to rinse the reactor and in-line filtered to 20 L rotavapor flask. The filtered reaction mixture was concentrated under reduced pressure until most toluene has been distilled to furnish 4.4 kg acyl chloride as dark oil.
- the addition was a little exothermic and a brown mixture was obtained after the addition.
- the reaction mixture was stirred at -10 to 0 °C for 20 min. and then warmed to 15 to 25 °C and stirred for 10 min.
- the layers were separated and the bottom organic layer was collected and the top aqueous layer was extracted with dichloromethane (7.7 L).
- the aqueous layer was discarded and the combined organic layers were transferred to 100 L jacketed reactor and washed with 15 wt % sodium chloride solution (11.6 L).
- the layers were separated and the bottom organic layer was collected and the top aqueous layer was extracted with dichloromethane (3.9 L).
- the aqueous layer was discarded and the combined organic layers were concentrated under reduced pressure until most dichloromethane was removed.
- Tetrahydrofuran (7.7 L) was charged to this dark oil and concentrated under reduced pressure until most tetrahydrofuran was removed to furnish intermediate (2') as dark oil (4.6 kg, 86% yield, 0.01 wt% water content by KF, 98.9% pure by HPLC).
- reaction mixture was stirred at below -55 °C for 10 min. Then 2 N HCl (10.7 L, 21.6 moles, 1.14 equiv.) was charged over 2 min. to quench the reaction while maintaining the reaction temperature below 20 °C (exotherms from -65 °C to 18 °C).
- ethyl acetate 39 L was charged in advance to 100 L jacketed reaction vessel and the above reaction mixture from 50 L round bottom flask was quickly transferred to 100 L jacketed reaction vessel containing ethyl acetate. 20% citric acid (10.5 L, 10.93 moles, 0.57 equiv.) was charged to adjust the batch pH ⁇ 4-5 and stirred for 5 min. The bottom aqueous layer was discarded and the top ethyl acetate layer was collected and washed twice with 15 wt % sodium chloride solution (9.0 L per wash). The organic layer was in-line filtered and concentrated under reduced pressure to a volume of 9.0 L.
- the reaction mixture was stirred at 75 to 80 °C over 21 h and a brown solution was obtained.
- the reaction was completed by HPLC (area/area % (6'): (7') ).
- the reaction mixture was cooled to 0 to 5 °C over 40 min. while vigorously stirring and solids precipitated out at 28 to 30°C.
- Water (39.6 L) was charged slowly via an addition funnel over 2 h 20 min. while maintaining the reaction temperature between 0 and 10 °C.
- the slurry was stirred at 0 to 5 °C over 30 min.
- the resulting slurry was filtered through an 18 inch Buchner funnel.
- the filtrate was concentrated under reduced pressure to a volume of 9.4 L to give a slurry and tetrahydrofuran was then solvent exchanged to methanol under reduced pressure via continuously feeding methanol (22.5 L).
- the final volume after solvent exchange was 11.2 L and the tetrahydrofuran content was confirmed to be ⁇ 1 wt% by 1 H-NMR.
- the resulting slurry was filtered through an 18 inch Buchner funnel and the filter cake was washed with methanol (3.7 L). The wet cake was dried on the filter for 25 min. and then dried under vacuum at 40 °C over 4 h until constant weight to furnish intermediate (9') as a white solid (1.54 kg, 90% yield, 98.4% pure by HPLC).
- Ammonium hydroxide 28 to 30% solution in water, 7.7 L, 57.3 moles, 4.7 equiv.
- methyl t-butyl ether 7.7 L
- the condenser temp. was set to be below -10 °C and to minimize the evaporation of ammonium hydroxide).
- the mixture was warmed to 23 to 28 °C.
- 2,2-Bis(trifluoromethyl)oxirane ((12) , 2.2 kg, 12.22 moles, 1.0 equiv.) was charged via an addition funnel over 1 h while maintaining the reaction temperature between 20 to 30 °C.
- the reaction mixture was stirred at 20 to 30 °C over 3 h after addition.
- the layers were allowed to separate for 30 min. and the bottom aq. layer was extracted twice with methyl t-butyl ether (2 x 7.7 L). The aqueous layer was discarded and the combined organic layers were concentrated under reduced pressure to a volume of 6.6 L.
- Methyl t-butyl ether (11 L) was continuously charged and concentrated to a volume of 6.6 L.
- Methyl t-butyl ether (44 L) and water (18 L) were then charged to the reaction mixture.
- the organic layer was washed with 1N HCl (10.6 L, 10.6 moles, 2.6 equiv.), followed by water (9.1 L).
- the organic layer was then concentrated under reduced pressure to a volume of 13.6 L.
- Methyl t-butyl ether (7.6 L) was charged and continued to concentrate under reduced pressure to a volume of 13.6 L.
- the organic layer was then transferred to a 100 L reactor via in-line filtration.
- Methyl t-butyl ether (4.5 L) was charged to the 100 L reactor via the transfer line to bring the volume to 18.1 L.
- the MTBE solution was heated to 50 to 56 °C and heptane (18.1 L) was charged via an addition funnel over 1 h 30 min while maintaining the reaction temperature above 50 °C to obtain a slurry.
- the resulting slurry was cooled to 15 to 25 °C and stirred at 15 to 25 °C over 30 min.
- the slurry was filtered through an 18 inch Buchner funnel, and the filter cake was washed with a pre-mixed solution of MTBE and heptane (4.5 L/9.0 L).
- the filter cake was dried on the filter for 1 h and then dried under vacuum at 40 °C over 4 h to furnish Compound I as an off-white solid (1.625 kg, 75% yield).
- the resulting slurry was cooled to 40 to 50 °C over 1 hour and stirred at 40 to 50 °C over 2 hours.
- the slurry was filtered and the solid cake was rinsed with acetonitrile/water (110 mL, 1/1 v/v) and dried under vacuum at 35 to 45 °C over 16 h to furnish the compound of Formula X as an off-white solid (27.9 g, 91% yield, 99% pure by HPLC).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (12)
- Procédé permettant la préparation d'un composé de formule II :R1 représente un cycle phényle non substitué ou un cycle hétéroaryle de 5 à 6 chaînons contenant jusqu'à trois hétéroatomes cycliques indépendamment choisis parmi un atome N, O ou S;R2 représente un cycle phényle ou un cycle hétéroaryle de 6 chaînons, éventuellement substitué par jusqu'à trois instances de R5; ledit cycle hétéroaryle de 6 chaînons contenant jusqu'à 2 atomes cycliques d'azote ; etchaque groupe R5 est indépendamment choisi parmi un groupe C1-6 alkyle, C1-6 alcoxy ou un atome d'halogène ;ledit procédé comprenant les étapes de :i) amidation de la substance de départ (1)en la faisant réagir avec une quantité appropriée de chlorure d'oxalyle ou d'un réactif équivalent, dans un mélange adéquat d'eau et d'un solvant organique aprotique, à une température adéquate, en présence d'une quantité appropriée d'un catalyseur adéquat ; suivie d'une quantité appropriée de chlorhydrate de N,O-diméthylhydroxylamine, en présence d'un excès approprié d'une base adéquate, à une température adéquate, dans un mélange adéquat d'eau et d'un solvant organique aprotique pour procurer l'amide (2) ;dans lequel R1 représente un cycle phényle non substitué ou un cycle hétéroaryle de 5 à 6 chaînons contenant jusqu'à trois hétéroatomes cycliques indépendamment choisis parmi l'atome N, O ou S ;ii) alkylation de l'amide intermédiaire (2) avec une quantité appropriée de propiolate d'éthyle, dans un solvant organique aprotique adéquat, à une température adéquate, en présence d'une quantité appropriée d'une base adéquate, pour procurer le β-énaminocétoester (3) ;iii) condensation du β-énaminocétoester (3) avec une quantité appropriée d'hydrazine de formule R2-CH2-NH-NH2 ou de son sel de HCl, éventuellement en présence d'une quantité appropriée d'une base adéquate, dans un solvant protique adéquat, à une température adéquate, qui procure l'intermédiaire d'ester de pyrazole (4)iv) amination de l'intermédiaire d'ester de pyrazole (4) avec une quantité appropriée de chlorure d'ammonium, en présence d'une quantité appropriée de triméthylaluminium, dans un solvant organique aprotique adéquat, à une température adéquate, qui procure l'amidine (5A), ou, après traitement avec un acide minéral aqueux adéquat, le sel d'amidine (5B) :v) condensation de l'amidine (5A) ou du sel d'amidine (5B) et d'une quantité appropriée de fluoromalonate, éventuellement en présence d'une quantité appropriée d'une base adéquate, dans un solvant protique adéquat, à une température adéquate pour procurer, après traitement avec une quantité appropriée d'un acide minéral adéquat, le diol (6)vi) chloration du diol (6) avec une quantité appropriée de chlorure de phosphoryle, à une température adéquate, dans un solvant organique aprotique adéquat, éventuellement en présence d'une quantité appropriée d'une base adéquate, pour procurer la dichloropyrimidine (7)vii) mono-méthoxylation de la dichloropyrimidine (7) avec une quantité appropriée de méthoxyde de sodium, à une température adéquate, dans un solvant protique approprié, pour procurer la méthoxypyrimidine (8)viii) dé-chloration de la méthoxypyrimidine (8) avec de l'hydrogène gazeux ou un réactif d'hydrogénation par transfert et, éventuellement, une quantité appropriée d'un catalyseur métallique adéquat, en présence d'une quantité appropriée d'une base adéquate, à une température adéquate, dans un solvant organique approprié, pour produire la fluorométhoxypyrimidine (9)ix) dé-méthylation de la fluorométhoxypyrimidine (9) en la faisant réagir avec une quantité appropriée d'un acide aqueux dans un solvant protique approprié, à une température adéquate, pour procurer l'alcool (10)x) chloration de l'alcool (10) avec une quantité appropriée de chlorure de phosphoryle et éventuellement une quantité appropriée d'une base adéquate, à une température adéquate, dans un solvant organique aprotique adéquat.
- Procédé permettant la préparation d'un composé de formule II :R1 représente un cycle phényle non substitué ou un cycle hétéroaryle de 5 à 6 chaînons contenant jusqu'à trois hétéroatomes cycliques indépendamment choisis parmi l'atome N, O ou S;R2 représente un cycle phényle ou un cycle hétéroaryle de 6 chaînons, tous deux éventuellement substitués par jusqu'à trois instances de R5 ; ledit cycle hétéroaryle de 6 chaînons contenant jusqu'à 2 atomes cycliques d'azote ; etchaque R5 est indépendamment choisi parmi un groupe C1-6 alkyle, C1-6 alcoxy ou un atome d'halogène ;ledit procédé comprenant les étapes de :1) mono-hydroxylation d'une dichloropyrimidine (7)2) dé-chloration de l'hydroxypyrimidine (8B) avec de l'hydrogène gazeux ou un réactif d'hydrogénation par transfert et, éventuellement, une quantité appropriée d'un catalyseur métallique adéquat, en présence d'une quantité appropriée d'une base adéquate, à une température adéquate, dans un solvant organique adéquat, pour fournir la fluorohydroxypyrimidine (10) ;3) chloration de l'alcool de fluorohydroxypyrimidine (10) avec une quantité appropriée de chlorure de phosphoryle et éventuellement une quantité appropriée d'une base adéquate, à une température adéquate, dans un solvant organique aprotique adéquat.
- Procédé selon la revendication 1 permettant la préparation d'un composé de formule IVi) amidation de la substance de départ (1')ii) alkylation de l'amide intermédiaire (2') avec une quantité appropriée de propiolate d'éthyle, dans un solvant organique aprotique adéquat, à une température adéquate, en présence d'une quantité appropriée d'une base adéquate, pour procurer le β-énaminocétoester (3')iii) condensation du β-énaminocétoester (3') avec une quantité appropriée d'une hydrazine de formule NH2NH-CH2-(2-fluorophényle) ou de son sel de HCl, éventuellement en présence d'une quantité appropriée d'une base adéquate, dans un solvant protique adéquat, à une température adéquate, qui procure l'intermédiaire d'ester de pyrazole (4')iv) amination de l'intermédiaire d'ester de pyrazole (4') avec une quantité appropriée de chlorure d'ammonium, en présence d'une quantité appropriée de triméthylaluminium, dans un solvant organique aprotique adéquat, à une température adéquate, qui procure l'amidine (5'A), ou, après traitement avec un acide minéral aqueux adéquat, le sel d'amidine (5'B) ;v) condensation de l'amidine (5'A) ou du sel d'amidine (5'B) et d'une quantité appropriée de fluoromalonate, éventuellement en présence d'une quantité appropriée d'une base adéquate, dans un solvant protique adéquat, à une température adéquate pour procurer, après traitement avec une quantité appropriée d'un acide minéral adéquat, le diol (6') ;vi) chloration du diol (6') avec une quantité appropriée de chlorure de phosphoryle, à une température adéquate, dans un solvant organique aprotique adéquat, éventuellement en présence d'une quantité appropriée d'une base adéquate, pour procurer la dichloropyrimidine (7') ;vii) mono-méthoxylation de la dichloropyrimidine (7') avec une quantité appropriée de méthoxyde de sodium, à une température adéquate, dans un solvant protique approprié, pour procurer la méthoxypyrimidine (8') ;viii) dé-chloration de la méthoxypyrimidine (8') avec de l'hydrogène gazeux ou un réactif d'hydrogénation par transfert et, éventuellement, une quantité appropriée d'un catalyseur métallique adéquat, en présence d'une quantité appropriée d'une base adéquate, à une température adéquate, dans un solvant organique approprié, pour produire la fluorométhoxypyrimidine (9') ;xi) dé-méthylation de la fluorométhoxypyrimidine (9') en la faisant réagir avec une quantité appropriée d'un acide aqueux, dans un solvant protique approprié, à une température adéquate, pour procurer l'alcool (10') ;x) chloration de l'alcool (10') avec une quantité appropriée de chlorure de phosphoryle et, éventuellement, une quantité appropriée d'une base adéquate, à une température adéquate, dans un solvant organique aprotique adéquat.
- Procédé selon la revendication 2, permettant la préparation d'un composé de formule IV1) mono-hydroxylation d'une dichloropyrimidine (7')2) dé-chloration de l'hydroxypyrimidine (8'B) avec de l'hydrogène gazeux et un réactif d'hydrogénation par transfert et, éventuellement, une quantité appropriée d'un catalyseur métallique adéquat, en présence d'une quantité appropriée d'une base adéquate, à une température adéquate, dans un solvant organique adéquat, pour produire la fluorohydroxypyrimidine (10') ;3) chloration de l'alcool (10') avec une quantité appropriée de chlorure de phosphoryle et éventuellement une quantité appropriée d'une base adéquate, à une température adéquate, dans un solvant organique aprotique adéquat.
- Procédé selon la revendication 1 ou 2, R1 représentant un cycle hétéroaryle de 5 chaînons contenant jusqu'à trois hétéroatomes indépendamment choisis parmi l'atome N, O ou S.
- Procédé selon la revendication 5, R1 représentant un groupe isoxazolyle.
- Procédé selon la revendication 5, R1 représentant un groupe 3-isoxazolyle.
- Procédé selon la revendication 1 ou 2, R2 représentant un cycle phényle éventuellement substitué par jusqu'à trois instances de R5.
- Procédé selon la revendication 8, R2 représentant un cycle phényle substitué par une instance de R5, R5 représentant un atome d'halogène.
- Procédé selon la revendication 9, R5 représentant un groupe fluoro.
- Procédé selon la revendication 8, R2 représentant un cycle phényle substitué par deux instances de R5 ; chaque instance de R5 étant indépendamment choisie parmi un atome d'halogène.
- Procédé selon la revendication 11, chaque instance de R5 représentant un groupe fluoro.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP23185002.5A EP4249488A3 (fr) | 2016-07-07 | 2017-07-06 | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662359453P | 2016-07-07 | 2016-07-07 | |
PCT/US2017/040810 WO2018009597A1 (fr) | 2016-07-07 | 2017-07-06 | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23185002.5A Division EP4249488A3 (fr) | 2016-07-07 | 2017-07-06 | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
EP23185002.5A Division-Into EP4249488A3 (fr) | 2016-07-07 | 2017-07-06 | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3481818A1 EP3481818A1 (fr) | 2019-05-15 |
EP3481818B1 true EP3481818B1 (fr) | 2023-09-06 |
EP3481818C0 EP3481818C0 (fr) | 2023-09-06 |
Family
ID=59416789
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17745553.2A Active EP3481818B1 (fr) | 2016-07-07 | 2017-07-06 | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
EP23185002.5A Pending EP4249488A3 (fr) | 2016-07-07 | 2017-07-06 | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23185002.5A Pending EP4249488A3 (fr) | 2016-07-07 | 2017-07-06 | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
Country Status (16)
Country | Link |
---|---|
US (3) | US11319308B2 (fr) |
EP (2) | EP3481818B1 (fr) |
JP (1) | JP7112384B2 (fr) |
KR (1) | KR102487872B1 (fr) |
CN (1) | CN109563077A (fr) |
AU (1) | AU2017291827B2 (fr) |
BR (1) | BR112019000291A2 (fr) |
CA (1) | CA3029375A1 (fr) |
CL (2) | CL2019000016A1 (fr) |
EA (1) | EA201990237A1 (fr) |
ES (1) | ES2963563T3 (fr) |
IL (1) | IL263995B (fr) |
MA (1) | MA45603A (fr) |
MX (2) | MX2019000105A (fr) |
SG (1) | SG11201900096QA (fr) |
WO (1) | WO2018009597A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018009602A2 (fr) | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
KR102487872B1 (ko) | 2016-07-07 | 2023-01-12 | 사이클리온 테라퓨틱스, 인크. | 가용성 구아닐레이트 시클라제 자극제의 신규 제조 방법 |
WO2019161534A1 (fr) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble |
EP4249469A3 (fr) | 2018-01-10 | 2023-12-27 | Cyclerion Therapeutics, Inc. | Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX351368B (es) * | 2010-05-26 | 2017-10-12 | Sunovion Pharmaceuticals Inc | Compuestos heteroarilo y metodos para utilizarlos. |
WO2012003405A1 (fr) | 2010-06-30 | 2012-01-05 | Ironwood Pharmaceuticals, Inc. | Stimulateurs de sgc |
CA2861804C (fr) * | 2011-12-27 | 2021-10-26 | Ironwood Pharmaceuticals, Inc. | Pyrazoles 2-benzyle, 3-(pyrimidin-2-yle)-substitues utiles comme stimulateurs de scg |
CA2885645A1 (fr) * | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Stimulateurs de sgc |
AU2014227862C1 (en) * | 2013-03-15 | 2019-05-30 | Cyclerion Therapeutics, Inc. | sGC stimulators |
CN106304835A (zh) * | 2013-12-11 | 2017-01-04 | 铁木医药有限公司 | sGC刺激剂 |
CA2961531A1 (fr) * | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Stimulateurs de la sgc |
AU2015317824A1 (en) * | 2014-09-17 | 2017-03-23 | Cyclerion Therapeutics, Inc. | Pyrazole derivatives as sGC stimulators |
MX2017003518A (es) * | 2014-09-17 | 2017-07-28 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
WO2016044445A2 (fr) * | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Stimulateurs de sgc |
WO2017095697A1 (fr) * | 2015-11-30 | 2017-06-08 | Ironwood Pharmaceuticals, Inc. | Dispersions solides comprenant un stimulateur de guanylate cyclase soluble (sgc) |
WO2018009602A2 (fr) | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
KR102487872B1 (ko) | 2016-07-07 | 2023-01-12 | 사이클리온 테라퓨틱스, 인크. | 가용성 구아닐레이트 시클라제 자극제의 신규 제조 방법 |
MA45588A (fr) * | 2016-07-07 | 2019-05-15 | Ironwood Pharmaceuticals Inc | Formes solides d'un stimulateur de la gcs |
BR112020012629A2 (pt) * | 2017-12-19 | 2020-12-01 | Cyclerion Therapeutics, Inc. | estimulantes de sgc |
EP4249469A3 (fr) * | 2018-01-10 | 2023-12-27 | Cyclerion Therapeutics, Inc. | Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble |
-
2017
- 2017-07-06 KR KR1020197003459A patent/KR102487872B1/ko active IP Right Grant
- 2017-07-06 CN CN201780047020.6A patent/CN109563077A/zh active Pending
- 2017-07-06 EA EA201990237A patent/EA201990237A1/ru unknown
- 2017-07-06 AU AU2017291827A patent/AU2017291827B2/en active Active
- 2017-07-06 MA MA045603A patent/MA45603A/fr unknown
- 2017-07-06 US US16/315,218 patent/US11319308B2/en active Active
- 2017-07-06 JP JP2019500355A patent/JP7112384B2/ja active Active
- 2017-07-06 WO PCT/US2017/040810 patent/WO2018009597A1/fr unknown
- 2017-07-06 CA CA3029375A patent/CA3029375A1/fr active Pending
- 2017-07-06 EP EP17745553.2A patent/EP3481818B1/fr active Active
- 2017-07-06 SG SG11201900096QA patent/SG11201900096QA/en unknown
- 2017-07-06 BR BR112019000291A patent/BR112019000291A2/pt unknown
- 2017-07-06 MX MX2019000105A patent/MX2019000105A/es unknown
- 2017-07-06 ES ES17745553T patent/ES2963563T3/es active Active
- 2017-07-06 EP EP23185002.5A patent/EP4249488A3/fr active Pending
-
2018
- 2018-12-27 IL IL263995A patent/IL263995B/en active IP Right Grant
-
2019
- 2019-01-04 CL CL2019000016A patent/CL2019000016A1/es unknown
- 2019-01-07 MX MX2022001495A patent/MX2022001495A/es unknown
-
2022
- 2022-03-30 US US17/708,296 patent/US11773089B2/en active Active
-
2023
- 2023-01-24 CL CL2023000228A patent/CL2023000228A1/es unknown
- 2023-08-24 US US18/237,435 patent/US20240059684A1/en active Pending
Non-Patent Citations (1)
Title |
---|
TAKASHI NAKAI ET AL: "Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans", ACS MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 5, 12 May 2016 (2016-05-12), US, pages 465 - 469, XP055406060, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.5b00479 * |
Also Published As
Publication number | Publication date |
---|---|
US11319308B2 (en) | 2022-05-03 |
AU2017291827B2 (en) | 2021-10-21 |
US11773089B2 (en) | 2023-10-03 |
KR102487872B1 (ko) | 2023-01-12 |
ES2963563T3 (es) | 2024-03-27 |
MA45603A (fr) | 2019-05-15 |
CA3029375A1 (fr) | 2018-01-11 |
EP4249488A2 (fr) | 2023-09-27 |
IL263995A (en) | 2019-02-28 |
SG11201900096QA (en) | 2019-02-27 |
MX2022001495A (es) | 2022-03-11 |
JP7112384B2 (ja) | 2022-08-03 |
US20210323951A1 (en) | 2021-10-21 |
US20220227748A1 (en) | 2022-07-21 |
MX2019000105A (es) | 2019-04-22 |
EP4249488A3 (fr) | 2023-12-20 |
EP3481818A1 (fr) | 2019-05-15 |
AU2017291827A1 (en) | 2019-02-07 |
CL2019000016A1 (es) | 2019-05-03 |
WO2018009597A1 (fr) | 2018-01-11 |
IL263995B (en) | 2021-02-28 |
BR112019000291A2 (pt) | 2019-04-16 |
JP2019525913A (ja) | 2019-09-12 |
US20240059684A1 (en) | 2024-02-22 |
EP3481818C0 (fr) | 2023-09-06 |
CL2023000228A1 (es) | 2023-09-29 |
CN109563077A (zh) | 2019-04-02 |
KR20190025986A (ko) | 2019-03-12 |
EA201990237A1 (ru) | 2019-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017206213B2 (en) | Processes for making compounds useful as inhibitors of ATR kinase | |
US11773089B2 (en) | Process for preparation of soluble guanylate cyclase stimulators | |
US20240199595A1 (en) | Novel processes for preparation of soluble guanylate cyclase stimulators | |
JP7397452B2 (ja) | ヘテロアリールカルボキシアミド化合物 | |
US12030874B2 (en) | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | |
WO2021188880A1 (fr) | Dérivés de benzènesulfonamide en tant que modulateurs trap1 et utilisations associées | |
US20220348590A1 (en) | Cyclooxygenase-2 inhibitors and uses thereof | |
OA19467A (en) | Novel processes for preparation of soluble Guanylate Cyclase stimulators. | |
EA041479B1 (ru) | Новые способы получения промежуточных соединений для синтеза стимуляторов растворимой гуанилатциклазы | |
OA19466A (en) | Novel processes for preparation of soluble Guanylate Cyclase stimulators. | |
EA040047B1 (ru) | Новые способы получения стимуляторов растворимой гуанилатциклазы | |
WO2021188911A1 (fr) | Dérivés de sulfonamide cycliques comme modulateurs de trap1 et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190121 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KARNATI, VISHNU VARDHAN REDDY Inventor name: XUE, SONG Inventor name: LIVINGSTON, ROBERT C. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CYCLERION THERAPEUTICS, INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200409 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40007031 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20210930 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20220622 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CYCLERION THERAPEUTICS, INC. |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LIVINGSTON, ROBERT C. Inventor name: KARNATI, VISHNU VARDHAN REDDY Inventor name: XUE, SONG |
|
INTG | Intention to grant announced |
Effective date: 20221128 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017073787 Country of ref document: DE |
|
U01 | Request for unitary effect filed |
Effective date: 20231005 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20231017 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231207 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231206 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231207 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2963563 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240327 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240106 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 |
|
VS25 | Lapsed in a validation state [announced via postgrant information from nat. office to epo] |
Ref country code: MD Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017073787 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20240607 |